Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge advises Blue Wolf Capital Partners in connection with the acquisition of seven manufacturing and development facilities from Recipharm

Vinge has, together with Kirkland & Ellis, advised Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, in connection with the acquisition of seven manufacturing and development facilities in Sweden, France, and Spain, from Recipharm Group, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.
September 03, 2024

Vinge advises on the sale of Märta Måås-Fjetterström’s business

Vinge has advised the Swedrup family in connection with the sale of Märta Måås-Fjetterström, Verkstaden för svenska mattor och vävnader Aktiebolag. The company manufactures rugs and tapestries in Båstad based on designs by both Märta Måås-Fjetterström herself and her successors, such as Barbro Nilsson, Marianne Richter, Ann-Mari Forsberg and others. The buyer is the Hult family.
September 03, 2024

Vinge advises Ingrid Capacity in its partnership with SEB Nordic Energy’s portfolio company Locus Energy

Vinge has advised Ingrid Capacity in connection with the entering into a strategic partnership with Locus Energy, a leading Nordic energy infrastructure company owned by SEB Asset Management's fund SEB Nordic Energy.
September 03, 2024